Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis
Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis
复制标题
DOI：
10.1007/s11926-017-0652-x
复制
发表时间：
2017-05-01
影响因子：
5
通讯作者：
Paterson, Kade L.
中科院分区：
文献类型：
--
作者：
Bennell, Kim L.;Hunter, David J.;Paterson, Kade L.
膝关节和髋关节骨关节炎（OA）是全球主要的公共卫生问题，导致疼痛，残疾和生活质量受损。这篇叙述性论文讨论了富血小板血浆（PRP）作为髋关节和膝关节OA的治疗方法，重点关注来自随机对照试验（RCTs）的证据。最近的发现自2012年PRP的第一个RCTs以来，已有15个RCTs用于膝关节OA，3个用于髋关节OA，主要比较PRP与另一种关节内注射疗法透明质酸。所有研究均为低至中等方法学质量，并使用可变PRP方案。总体而言，结果表明PRP是一种安全的治疗方法，至少在短期内（长达12个月）可能为OA提供症状获益。病情较轻的年轻患者可能更敏感。没有RCT调查PRP对OA结构变化的影响。总结鉴于方法学问题和研究之间的相当大的异质性，无法得出关于PRP在OA中的影响的明确结论。需要进一步的高质量研究来确定PRP的临床和成本效益，最有可能受益的患者和最佳PRP方案。
Purpose of Review Knee and hip osteoarthritis (OA) are major public health problems worldwide causing pain, disability and impaired quality of life. This narrative paper discusses platelet-rich plasma (PRP) as a treatment for hip and knee OA, with a focus on evidence from randomised controlled trials (RCTs).Recent Findings Since the first RCTof PRP in 2012, there has been 15 RCTs in knee OA and three in hip OA, mostly comparing PRP to another intra-articular injection therapy, hyaluronic acid. All studies are of low to moderate methodological quality and use variable PRP protocols. In general, results showed that PRP is a safe treatment with potential to provide symptomatic benefit for OA at least in the short term (up to 12 months). Younger patients with less severe disease may be more responsive. There are no RCTs investigating the effects of PRP on OA structural changes.Summary No definitive conclusions can be made about the effects of PRP in OA given methodological concerns and considerable heterogeneity between studies. Further high-quality research is needed to establish the clinical and cost-effectiveness of PRP, the patients most likely to benefit and the optimal PRP protocol.